There are several types of NETs, including Gastro Intestinal (GI NETS), Pancreatic (PNETS), Lung NETS, medullary thyroid carcinomas (MTCs), pheochromocytomas, and neuroendocrine carcinomas of the skin (Merkel Cell Cancer). Treatment depends on the type of tumor and its location, whether it produces excess hormones, how aggressive it is, and whether it has spread. Advances in treatment have improved the length of survival for patients with NETs.
While relatively rare, NETs have the second largest prevalence of all GI cancers (colon is the largest), because many people continue to live with the disease. Over the last several decades the incidence (number of new diagnoses) has also been rising, which might be due to more awareness, improved diagnostic tools, or a change in definition.
What is molecular imaging?
Molecular imaging is a type of medical imaging that provides detailed pictures of what is happening inside the body at the molecular or cellular level. Where other diagnostic imaging procedures-such as x-rays, computed tomography (CT) and ultrasound-predominantly offer anatomical pictures, molecular imaging allows physicians to see how the body is functioning and to measure its chemical and biological processes.
Molecular imaging offers unique insights into the human body that enable physicians to personalize patient care. In terms of diagnosis, molecular imaging is able to:
 provide information that is unattainable with other imaging technologies or that would require more invasive procedures such as biopsy or surgery  identify disease in its earliest stages and determine the exact location of a tumor, often before symptoms occur or abnormalities can be detected with other diagnostic tests As a tool for evaluating and managing the care of patients, molecular imaging studies help physicians:  determine the extent or severity of the disease, including whether it has spread elsewhere in the body  select the most effective therapy based on the unique biologic characteristics of the patient and the molecular properties of a tumor or other disease  determine a patient's response to specific drugs  accurately assess the effectiveness of a treatment regimen  adapt treatment plans in response to changes in cellular activity  assess disease progression  identify recurrence of disease and help manage ongoing care Molecular imaging procedures are noninvasive, safe, and painless.
How does molecular imaging work?
When disease occurs, the biochemical activity of cells begins to change. For example, some cancer cells multiply at a much faster rate and are more active than normal cells. Brain cells affected by dementia consume less energy than normal brain cells. Heart cells deprived of adequate blood flow begin to die.
As disease progresses, this abnormal cellular activity begins to affect body tissue and structures, causing anatomical changes that may be seen on CT or MRI scans. For example, cancer cells may form a mass or tumor. With the loss of brain cells, overall brain volume may decrease or affected parts of the brain may appear different in density than the normal areas. Similarly, the heart muscle cells that are affected stop contracting and the overall heart function deteriorates.
Molecular imaging excels at detecting the cellular changes that occur early in the course of disease, often well before structural changes can be seen on CT and MR images.
Most molecular imaging procedures involve an imaging device and an imaging agent, or probe. A variety of imaging agents are used to visualize cellular activity, such as the chemical processes involved in metabolism, oxygen use, or blood flow. In nuclear medicine, which is a branch of molecular imaging, the imaging agent is a radiotracer, a compound that includes a radioactive atom, or isotope. Other molecular imaging modalities, such as optical imaging and molecular ultrasound, use a variety of different agents. Magnetic resonance (MR) spectroscopy is able to measure chemical levels in the body, without the use of an imaging agent.
Once the imaging agent is introduced into the body, it accumulates in a target organ or attaches to specific cells. The imaging device detects the imaging agent and creates pictures that show how it is distributed in the body. This distribution pattern helps physicians discern how well organs and tissues are functioning.
How is molecular imaging helping people with NETs?
A majority of NETs produce an abundance (called overexpression) of a specific cell feature called somatostatin receptors. Molecular imaging technologies use this cell feature to detect cancerous cells throughout the body and as a target for the delivery of therapy.
Physicians are using molecular technologies to:  diagnose and stage: used to find NETS throughout the body. The patient is injected with a drug called octreotide -a synthetic form of the naturally occurring hormone somatostatin -that is chemically bound to a radioisotope, either indium-111 or 68Ga. The radioactive octreotide attaches to tumor cells that have somatostatin receptors and is detected by either a SPECT or PET/CT machine that creates pictures showing where the tumor cells are in the body. Nearly 90 percent of NETs can be identified with Ga-DOTATATE (NETSPOT), which is a type of 68Ga PET/CT.
 deliver treatment: molecular radiotherapy (MRT) is a systemically administered, targeted therapy for cancer that delivers radiation at the cellular and molecular levels. In contrast to chemotherapy, wherein all proliferating cells are affected, MRT delivers radiation to only those cells that express cancer markers.
Peptide receptor radionuclide therapy (PRRT) is a highly targeted and effective form of MRT with minimal side effects for treating NETs with an abundance (or overexpression) of somatostatin receptors. In PRRT, the patient receives an intravenous injection of a drug such as octreotide that is chemically bound to (or radiolabeled with) a radioactive material, mainly lutetium-177. Other radionuclides include yttrium-90, or indium-111. The radioactive octreotide attaches to somatostatin receptors on tumor cells, which are destroyed by the radiation.
What are the advantages of molecular imaging technologies for people with NET?
 localization of disease (e.g., primary)  accurate evaluation of the extent of disease  evaluation of somatostatin receptors status prior to PRRT  information complementary to anatomic imaging is provided  In PRRT have been shown to have a treatment advantage over high-dose octreotide with minimal long-term side effects.
Is nuclear imaging (PET or SPECT) safe?
Many medical procedures have side effects and risks; the same is true of nuclear medicine diagnostic tests such as PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computerized Tomography). Each procedure takes a certain amount of radiation to perform appropriately. Used in the right way for the right patient at the right time, nuclear medicine is very safe-the benefits of the procedure very far outweigh the potential risks.
Is PRRT safe?
All medical therapies involve risks and can have both short-and long-term side effects. Please discuss with your treating physician the safety profile of PRRT treatments compared to other treatment options you may be considering.
Are molecular imaging technologies covered by insurance?
Check with your insurance company for specific information on your plan.
What is the future of molecular imaging of NET?
A multicenter, randomized, phase III study (NETTER-1) comparing treatment with different versions of octreotide in patients with inoperable, progressive, somatostatin receptor-positive midgut carcinoid tumors was completed with positive results in 2015. As of this writing (August 2017), the Federal Drug Administration is considering an application for the approval of PRRT using Lu177 Dotatate. Imaging with Ga-68 DOTATATE was approved in the United States in June 2016 to assist in locating NETs for staging and restaging and managing the ongoing care of patients. Researchers are continuing to study how to improve molecular imaging and therapy for those living with NET.
